The wilms tumor protein market size has grown strongly in recent years. It will grow from $3.09 billion in 2023 to $3.27 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period for products related to Wilms Tumor Protein (WT1) can be attributed to factors such as the incidence and diagnosis of cancer, increasing awareness, and collaborative efforts in cancer care.
The wilms tumor protein market size is expected to see strong growth in the next few years. It will grow to $4.06 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The forecasted growth in the coming period for products related to Wilms Tumor Protein (WT1) can be attributed to trends such as personalized medicine approaches, advancements in genomic and proteomic research, initiatives for patient advocacy and support, regulatory backing for precision medicine, and the integration of biomarker testing. Additionally, major trends include a focus on early detection and screening programs, adherence to regulatory standards in diagnostic assays, increased awareness through patient advocacy initiatives, integration of next-generation sequencing (NGS), and the global expansion of diagnostic services.
The escalating incidence of kidney cancers is poised to drive the growth of the Wilms tumor protein market in the foreseeable future. Kidney cancer, characterized by abnormal cell growth within kidney tissue, can benefit from WT1 expression analysis, especially in cases where tumors are minute or challenging to biopsy. For instance, as reported by the American Cancer Society in January 2023, approximately 81,800 new cases of kidney cancer and 14,890 deaths were recorded in 2023 in the United States. Additionally, projections by Cancer Research UK suggest an estimated 21,900 new cases of kidney cancer annually in the UK by 2038-2040. Consequently, the increasing instances of kidney cancers are expected to significantly propel the growth of the Wilms tumor protein market.
The expanding demand for personalized medicine is anticipated to fuel the growth trajectory of the Wilms tumor protein (WT1) market. Personalized medicine represents an innovative healthcare approach considering individual genetic, environmental, and lifestyle variations when designing patient-specific treatment strategies. WT1 serves as a promising target antigen for cancer immunotherapy, allowing the development of tailored immunotherapy based on its protein expression and clinical correlations for cancer patients. For example, in 2022, the Food and Drug Administration (FDA) in the United States approved 12 personalized medicines, constituting approximately 34% of all newly approved therapeutic molecular entities. Hence, the increasing demand for personalized medicine stands as a significant driver propelling the growth of the Wilms tumor protein (WT1) market.
The Wilms tumor protein (WT1) market is expected to face significant constraints due to the limited understanding of tumor heterogeneity in the future. Tumor heterogeneity refers to the diverse genetic, molecular, and cellular variances present within a single type of cancer, such as Wilms tumor. This complexity poses challenges in pinpointing specific drug targets, as conventional drug development often targets specific genetic or molecular irregularities found within cancer cells. The inherent heterogeneity of Wilms tumors complicates the development of uniform treatment approaches. For instance, a study published in a prominent medical journal in 2022 delved into the genetic and molecular heterogeneity of Wilms tumors in pediatric patients. These variations can significantly impact the tumor's aggressiveness, response to treatment, and overall prognosis. Therefore, the limited comprehension of tumor heterogeneity stands as a substantial obstacle impeding the growth of the Wilms tumor protein (WT1) market.
Key companies in the Wilms tumor protein market are directing efforts toward developing advanced detection methodologies, such as the enzyme-linked immunosorbent assay (ELISA), to offer dependable services to their market clientele. ELISA, a highly sensitive and specific method, employs specialized enzymes that bind to antibodies in the blood, detecting Host Cell Proteins (HCPs). For instance, in February 2023, Charles River Laboratories International Inc., a US-based entity specializing in novel drug and therapeutic development, introduced an Enzyme-Linked Immunosorbent Assay (ELISA) Kit designed for the detection and quantification of residual Host Cell Proteins (HCP). This innovative HCP-ELISA kit from Charles River utilizes avian IgY antibodies as its primary detection method. These specific antibodies, exclusively produced by AVS Bio from Specific-Pathogen-Free Chicken (SPF) Eggs, form a crucial component of this novel detection system.
In October 2021, Abcam plc, a United Kingdom-based manufacturer and supplier specializing in protein research tools, completed the acquisition of BioVision Inc. for a sum of $340 million. This strategic acquisition empowers Abcam to bolster its immunoassay capabilities in Eugene, fostering internal innovation and amplifying its reach within the markets for cellular and biochemical assays. BioVision Inc., a United States-based company, specializes in the development of premium assay kits, recombinant proteins, and W1 antibodies specifically related to the Wilms tumor protein.
Major companies operating in the wilms tumor protein market report are Thermo Fisher Scientific Inc., Abbott Laboratories, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd, Otsuka Holdings Co Ltd, Agilent Technologies Inc., Illumina Inc., Sumitomo Dainippon Pharma Co Ltd., PerkinElmer Inc., ZS Genetics Inc., Tecan Trading AG, QIAGEN NV, Abcam plc, Hamilton Company, BioLegend Inc., Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., Sino Biological Inc., LI-COR Inc., Cell Signaling Technology Inc., Genetex Inc., Proteintech Group Inc., Zymo Research Corporation, Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Inovio Pharmaceuticals Inc., OriGene Technologies Inc., Macrogen Inc., Boster Biological Technology, Vaximm Ag, Fitzgerald Industries International.
North America was the largest region in the wilms tumor protein market in 2023. The regions covered in the wilms tumor protein market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the wilms tumor protein market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The Wilms tumor protein market consists of revenues earned by entities by providing services such as genetic testing and counseling, cancer diagnosis, and treatment, and pediatric oncology services. The market value includes the value of related goods sold by the service provider or included within the service offering. The wilms tumor protein market also includes sales of polymerase chain reaction (PCR) primers and probes, and research kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The main types of products related to Wilms Tumor Protein include antibodies, assay kits, recombinant proteins, and others. Antibodies, also known as immunoglobulins, are proteins produced by the immune system in response to the presence of foreign substances, such as bacteria, viruses, or other pathogens. Various detection methods, such as immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), western blotting, polymerase chain reaction (PCR), and others, are applied in cancer diagnosis, cancer treatment, research and development, and other applications. End users include hospitals, diagnostic laboratories, research institutes, and others.
The wilms tumor protein market research report is one of a series of new reports that provides wilms tumor protein market statistics, including wilms tumor protein industry global market size, regional shares, competitors with a wilms tumor protein market share, detailed wilms tumor protein market segments, market trends and opportunities, and any further data you may need to thrive in the wilms tumor protein industry. This wilms tumor protein market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The wilms tumor protein market size is expected to see strong growth in the next few years. It will grow to $4.06 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The forecasted growth in the coming period for products related to Wilms Tumor Protein (WT1) can be attributed to trends such as personalized medicine approaches, advancements in genomic and proteomic research, initiatives for patient advocacy and support, regulatory backing for precision medicine, and the integration of biomarker testing. Additionally, major trends include a focus on early detection and screening programs, adherence to regulatory standards in diagnostic assays, increased awareness through patient advocacy initiatives, integration of next-generation sequencing (NGS), and the global expansion of diagnostic services.
The escalating incidence of kidney cancers is poised to drive the growth of the Wilms tumor protein market in the foreseeable future. Kidney cancer, characterized by abnormal cell growth within kidney tissue, can benefit from WT1 expression analysis, especially in cases where tumors are minute or challenging to biopsy. For instance, as reported by the American Cancer Society in January 2023, approximately 81,800 new cases of kidney cancer and 14,890 deaths were recorded in 2023 in the United States. Additionally, projections by Cancer Research UK suggest an estimated 21,900 new cases of kidney cancer annually in the UK by 2038-2040. Consequently, the increasing instances of kidney cancers are expected to significantly propel the growth of the Wilms tumor protein market.
The expanding demand for personalized medicine is anticipated to fuel the growth trajectory of the Wilms tumor protein (WT1) market. Personalized medicine represents an innovative healthcare approach considering individual genetic, environmental, and lifestyle variations when designing patient-specific treatment strategies. WT1 serves as a promising target antigen for cancer immunotherapy, allowing the development of tailored immunotherapy based on its protein expression and clinical correlations for cancer patients. For example, in 2022, the Food and Drug Administration (FDA) in the United States approved 12 personalized medicines, constituting approximately 34% of all newly approved therapeutic molecular entities. Hence, the increasing demand for personalized medicine stands as a significant driver propelling the growth of the Wilms tumor protein (WT1) market.
The Wilms tumor protein (WT1) market is expected to face significant constraints due to the limited understanding of tumor heterogeneity in the future. Tumor heterogeneity refers to the diverse genetic, molecular, and cellular variances present within a single type of cancer, such as Wilms tumor. This complexity poses challenges in pinpointing specific drug targets, as conventional drug development often targets specific genetic or molecular irregularities found within cancer cells. The inherent heterogeneity of Wilms tumors complicates the development of uniform treatment approaches. For instance, a study published in a prominent medical journal in 2022 delved into the genetic and molecular heterogeneity of Wilms tumors in pediatric patients. These variations can significantly impact the tumor's aggressiveness, response to treatment, and overall prognosis. Therefore, the limited comprehension of tumor heterogeneity stands as a substantial obstacle impeding the growth of the Wilms tumor protein (WT1) market.
Key companies in the Wilms tumor protein market are directing efforts toward developing advanced detection methodologies, such as the enzyme-linked immunosorbent assay (ELISA), to offer dependable services to their market clientele. ELISA, a highly sensitive and specific method, employs specialized enzymes that bind to antibodies in the blood, detecting Host Cell Proteins (HCPs). For instance, in February 2023, Charles River Laboratories International Inc., a US-based entity specializing in novel drug and therapeutic development, introduced an Enzyme-Linked Immunosorbent Assay (ELISA) Kit designed for the detection and quantification of residual Host Cell Proteins (HCP). This innovative HCP-ELISA kit from Charles River utilizes avian IgY antibodies as its primary detection method. These specific antibodies, exclusively produced by AVS Bio from Specific-Pathogen-Free Chicken (SPF) Eggs, form a crucial component of this novel detection system.
In October 2021, Abcam plc, a United Kingdom-based manufacturer and supplier specializing in protein research tools, completed the acquisition of BioVision Inc. for a sum of $340 million. This strategic acquisition empowers Abcam to bolster its immunoassay capabilities in Eugene, fostering internal innovation and amplifying its reach within the markets for cellular and biochemical assays. BioVision Inc., a United States-based company, specializes in the development of premium assay kits, recombinant proteins, and W1 antibodies specifically related to the Wilms tumor protein.
Major companies operating in the wilms tumor protein market report are Thermo Fisher Scientific Inc., Abbott Laboratories, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd, Otsuka Holdings Co Ltd, Agilent Technologies Inc., Illumina Inc., Sumitomo Dainippon Pharma Co Ltd., PerkinElmer Inc., ZS Genetics Inc., Tecan Trading AG, QIAGEN NV, Abcam plc, Hamilton Company, BioLegend Inc., Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., Sino Biological Inc., LI-COR Inc., Cell Signaling Technology Inc., Genetex Inc., Proteintech Group Inc., Zymo Research Corporation, Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Inovio Pharmaceuticals Inc., OriGene Technologies Inc., Macrogen Inc., Boster Biological Technology, Vaximm Ag, Fitzgerald Industries International.
North America was the largest region in the wilms tumor protein market in 2023. The regions covered in the wilms tumor protein market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the wilms tumor protein market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The Wilms tumor protein market consists of revenues earned by entities by providing services such as genetic testing and counseling, cancer diagnosis, and treatment, and pediatric oncology services. The market value includes the value of related goods sold by the service provider or included within the service offering. The wilms tumor protein market also includes sales of polymerase chain reaction (PCR) primers and probes, and research kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The main types of products related to Wilms Tumor Protein include antibodies, assay kits, recombinant proteins, and others. Antibodies, also known as immunoglobulins, are proteins produced by the immune system in response to the presence of foreign substances, such as bacteria, viruses, or other pathogens. Various detection methods, such as immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), western blotting, polymerase chain reaction (PCR), and others, are applied in cancer diagnosis, cancer treatment, research and development, and other applications. End users include hospitals, diagnostic laboratories, research institutes, and others.
The wilms tumor protein market research report is one of a series of new reports that provides wilms tumor protein market statistics, including wilms tumor protein industry global market size, regional shares, competitors with a wilms tumor protein market share, detailed wilms tumor protein market segments, market trends and opportunities, and any further data you may need to thrive in the wilms tumor protein industry. This wilms tumor protein market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary2. Wilms Tumor Protein Market Characteristics3. Wilms Tumor Protein Market Trends and Strategies32. Global Wilms Tumor Protein Market Competitive Benchmarking33. Global Wilms Tumor Protein Market Competitive Dashboard34. Key Mergers and Acquisitions in the Wilms Tumor Protein Market
4. Wilms Tumor Protein Market - Macro Economic Scenario
5. Global Wilms Tumor Protein Market Size and Growth
6. Wilms Tumor Protein Market Segmentation
7. Wilms Tumor Protein Market Regional and Country Analysis
8. Asia-Pacific Wilms Tumor Protein Market
9. China Wilms Tumor Protein Market
10. India Wilms Tumor Protein Market
11. Japan Wilms Tumor Protein Market
12. Australia Wilms Tumor Protein Market
13. Indonesia Wilms Tumor Protein Market
14. South Korea Wilms Tumor Protein Market
15. Western Europe Wilms Tumor Protein Market
16. UK Wilms Tumor Protein Market
17. Germany Wilms Tumor Protein Market
18. France Wilms Tumor Protein Market
19. Italy Wilms Tumor Protein Market
20. Spain Wilms Tumor Protein Market
21. Eastern Europe Wilms Tumor Protein Market
22. Russia Wilms Tumor Protein Market
23. North America Wilms Tumor Protein Market
24. USA Wilms Tumor Protein Market
25. Canada Wilms Tumor Protein Market
26. South America Wilms Tumor Protein Market
27. Brazil Wilms Tumor Protein Market
28. Middle East Wilms Tumor Protein Market
29. Africa Wilms Tumor Protein Market
30. Wilms Tumor Protein Market Competitive Landscape and Company Profiles
31. Wilms Tumor Protein Market Other Major and Innovative Companies
35. Wilms Tumor Protein Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Wilms Tumor Protein Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on wilms tumor protein market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for wilms tumor protein? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: Antibodies; Assay Kits; Recombinant Proteins; Other Types
2) By Detection Method: Immunohistochemistry (IHC); Enzyme-Linked Immunosorbent Assay (ELISA); Western Blotting; Polymerase Chain Reaction (PCR); Other Methods
3) By Application: Cancer Diagnosis; Cancer Treatment; Research and Development; Other Applications
4) By End User: Hospitals; Diagnostic Laboratories; Research Institutes; Other End Users
Key Companies Mentioned: Thermo Fisher Scientific Inc.; Abbott Laboratories; GlaxoSmithKline Plc; F. Hoffmann-La Roche Ltd; Otsuka Holdings Co Ltd
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Methodology
LOADING...
